Advances in magnetic resonance imaging contrast agents for glioblastoma-targeting theranostics

作     者：Zijun Wu Lixiong Dai Ke Tang Yiqi Ma Bin Song Yanrong Zhang Jinxing Li Su Lui Qiyong Gong Min Wu 

作者机构：Huaxi MR Research Center(HMRRC)Department of RadiologyFunctional and Molecular Imaging Key Laboratory of Sichuan ProvinceWest China HospitalSichuan UniversityChengdu 610041China Wenzhou InstituteUniversity of Chinese Academy of SciencesWenzhouZhejiang 325000China Department of RadiologySchool of MedicineStanford UniversityStanfordCA 94305USA 

出 版 物：《Regenerative Biomaterials》 (再生生物材料（英文版）)

年 卷 期：2021年第8卷第6期

页      面：273-296页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the Natural Science Foundation of China(Grant No.81501462,22075281) the Chengdu International Science and Technology Cooperation Funding(Grant No.2019-GH02-00074-HZ) the 135 project for disciplines of Excellence-Clinical Research Incubation Project,West China Hospital,Sichuan University the Scientific and technological Achievements Transformation Fund of West China Hospital,Sichuan University(Grant No.CGZH21002) the Functional and Molecular Imaging Key Laboratory of Sichuan Province(Grant No.2012JO0011) Zhejiang Provincial Natural Science of Foundation of China(LZ21B010001) University of Chinese Academy of Science(WIUCASQD2020008) 

主　　题：glioblastoma MRI targeted contrast agents therapy drug delivery 

摘      要：Glioblastoma(GBM)is the most aggressive malignant brain tumour,with a median survival of 3 months without treatment and 15 months with *** GBM diagnosis can significantly improve patient survival due to early treatment and management *** resonance imaging(MRI)using contrast agents is the preferred method for the preoperative detection of GBM ***,commercially available clinical contrast agents do not accurately distinguish between GBM,surrounding normal tissue and other cancer types due to their limited ability to cross the blood-brain barrier,their low relaxivity and their potential *** GBM-specific contrast agents are urgently needed to overcome the limitations of current contrast *** advances in nanotechnology have produced alternative GBM-targeting contrast *** surfaces of nanoparticles(NPs)can be modified with multimodal contrast imaging agents and ligands that can specifically enhance the accumulation of NPs at GBM *** advanced imaging technology,multimodal NP-based contrast agents have been used to obtain accurate GBM diagnoses in addition to an increased amount of clinical diagnostic *** can also serve as drug delivery systems for GBM *** review focuses on the research progress for GBMtargeting MRI contrast agents as well as MRI-guided GBM therapy.